CooperSurgical has acquired Embryo Options, offering cryo-storage software solutions for clinics and patients. The acquisition complements CooperSurgical’s portfolio of fertility offerings.
Clinics partnered with Embryo Options benefit from automated billing and streamlined management of cryo-preserved embryos, eggs, and sperm, resulting in increased collections, decreased specimen abandonment, and a reduced cost to manage cryo-inventory.
It has been estimated that more than 1 million cryopreserved embryos are currently being stored in the United States, and with the number of IVF cycles continuing to grow, this number is expected to increase significantly in the future.
“Embryo Options is a great addition to our portfolio of world-class solutions for assisted reproduction. Cryopreservation is an important and growing aspect of fertility offerings,” said Holly Sheffield, President, CooperSurgical. “I’m excited that Embryo Options furthers our goal of expanding patients’ access to the information and support they need to have a child.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
Embryo Options joins the CooperSurgical portfolio, which supports patient and clinicians’ needs throughout the entire fertility journey. Its brands include Origio®, Research Instruments®, TPC®, K-Systems®, Wallace® LifeGlobal® and CooperGenomicsSM.
“Our team is excited to join with CooperSurgical in bringing valuable new solutions to IVF facilities,” said Andy Gairani, Managing Director of Embryo Options. “The more we can expand our reach, the more we can help patients find solutions that are the right fit for them.”